Cell therapy

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy

This week in drug discovery (30 June – 4 July) 

News round-up for 30 June – 4 July by DDW Senior Digital Content Editor Diana Turner. In significant news this week, the FDA in the US has removed red tape that limits which centres could give CAR-T therapy, in a move to improve access to the therapies. The… Read More

#News

Human heart
#Cardiovascular disease #Cell therapy #Longeveron #Paediatrics #Phase II trial #Regenerative Medicine

Regenerative cell therapy for rare heart disease enters PhII trials

Longeveron has completed enrolment for its Phase IIb clinical trial (ELPIS II) evaluating cellular therapy laromestrocel as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS).  Laromestrocel is a scalable, allogeneic cellular therapy being evaluated in multiple indications.  Top-line trial results are anticipated in… Read More

#News

CAR-T cells attacking a cancer cell
#CAR-T #Cell therapy #Haematology #Oncology

Coalition aims to double CAR-T therapy access by 2030

CAR T Vision has launched to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR-T therapy.   By 2030, the coalition aims to double the proportion of eligible patients treated with CAR-T therapy.   As outlined in a… Read More

#News

#AbbVie #Capstan Therapeutics #CAR-T #Cell therapy #In vivo #Mergers and acquisitions

AbbVie acquires in vivo CAR-T technology with Capstan purchase

AbbVie has revealed it will acquire Capstan Therapeutics, a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs.  The acquisition will include CPTX2309, a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy candidate, currently in Phase I development for the treatment of B… Read More

#Business & Investment #News

FDA headquarters
#CAR-T #Cell therapy #FDA #Immunotherapy #Regulatory

FDA removes barriers to CAR-T access in the US

The Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies have been removed.  The Food and Drug Administration (FDA) has determined that a REMS is no longer necessary to ensure that the benefits of these CAR T cell immunotherapies… Read More

#News #Regulatory

Test for AMD
#Cell therapy #Clinical trial #Lineage Cell Therapeutics #Ophthalmology

Cell therapy improves visual function in geographic atrophy patients

Lineage Cell Therapeutics revealed new 36-month results from a Phase I/IIa clinical study of RG6501 (OpRegen) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) at Clinical Trials at the Summit (CTS) 2025.   OpRegen is a suspension of human allogeneic retinal pigment epithelial (RPE)… Read More

#News

Blood cancer
#Cell therapy #CHMP #European Commission #Haematology #Oncology #Stem cells

Stem cell therapy gets positive CHMP opinion for blood cancers

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting conditional marketing authorisation for Zemcelpro (UM171 cell therapy).  The positive opinion relates to the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following… Read More

#News #Regulatory

Human cell
#Cell therapy #Clinical trial #Diabetes #Type 1 diabetes #Vertex

Vertex shares new data for stem cell-derived islet therapy in T1D

Vertex Pharmaceuticals has shared new Phase I/II data for zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy.  The FORWARD-101 clinical trial is investigating the treatment in people with type 1 diabetes (T1D) with impaired hypoglycaemic awareness and severe hypoglycaemic events (SHEs).  All… Read More

#News

Cancer research
#ASCO #Cancer immunotherapy #Cancer research #Cell therapy #Oncology #Precision medicine #Therapeutics

Expert commentary from ASCO 2025

This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More

#Cancer Research #Exclusive Content

FDA
#Cell therapy #Cytokine Release Syndrome (CRS) #FDA #Orphan drugs #Poolbeg Pharma

Poolbeg granted FDA ODD for CRS cell therapy

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Poolbeg Pharma’s POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (CRS). The FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000… Read More

#News

CAR-T cell therapy
#CAR-T #Cell therapy #In Focus Report #Market reporting

In Focus report: Cell therapy and opportunities for new medicines

With significant investment in development and manufacturing, the cell therapy market is expected to boom in the next five years. However, despite the optimism around cell therapies, many are expensive, complicated to manufacture and come with potentially severe side effects. This report investigates how drug developers… Read More

#News

Gastrointestinal tract
#Cell and gene therapy #Cell therapy #CRISPR #Gastrointestinal #Gene editing #Oncology

CRISPR TIL therapy shows early success in GI cancers

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.   The results, published in Lancet Oncology, show encouraging signs of safety and potential… Read More

#Cancer Research #Editor's Choice #News

Human adenovirus
#biological engineering #CAR-T #Cell and gene therapy #Cell therapy #EsoBiotec #In vivo

Revolutionising cancer treatment with viral vectors

CAR-T cell therapy has revolutionised cancer treatment, offering life-changing outcomes for patients with haematological malignancies. Jean-Pierre Latere, PhD, CEO of EsoBiotec, discusses advances in in vivo engineering, which are poised to overcome manufacturing and cost barriers, making these therapies more accessible and expanding their potential applications. The landscape of cancer… Read More

#Cancer Research #Exclusive Content

#Antibodies #Cell analysis #Cell therapy #Drug discovery #Single-cell analysis

How real-time analysis of single cells can advance drug discovery  

DDW Editor Reece Armstrong speaks to Vikram Devgan, PhD, VP of Global Marketing and Product Management, Bruker Cellular Analysis, about how real-time access to single cells can drive functional insights.   RA: How has single-cell research evolved over the past two decades?  VD: Single-cell research has transitioned from immunophenotyping via flow… Read More

#Exclusive Content

#Artificial intelligence (AI) #CAR-T #Cell and gene therapy #Cell therapy

The future of cell therapy: AI has a role to play in breaking today’s barriers

Rafael Carazo Salas, CEO and Founder of CellVoyant, explores AI’s potential for cell therapies. AI is already making big strides in biotechnology and healthcare, from its remarkable accuracy in detecting breast cancer from mammograms, to AI platforms such as DeepMind’s AlphaFold revolutionising protein structure prediction. One of the most promising areas… Read More

#Exclusive Content